Clinical Trials: Design, Conduct and Analysis

Clinical Trials: Design, Conduct and Analysis

Volumn , Issue , 2009, Pages 1-494

  Meinert, Curtis L ^a  

^a NONE

Author keywords

Costs factors; Design principles; Execution; Follow up; Multicenter trials; Quality assurance; Sample size estimates; Single center trials; Treatment masking; Typical study

Indexed keywords

EID: 84939187269     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195035681.001.0001     Document Type: Book

References (505)

1. Abt K: Problems of repeated significance testing. Controlled Clin Trials 1:377-381, 1981.
2. Alamercery Y, Lo Presti F, Karisson T, Bowden G, and IMPACT Research Group: Functional equality of coordinating centers in a multicenter clinical trial:Experience of the International Mexiletine and Placebo Antiarrhythmic Coronary Trial:IMPACT (abstract). Controlled Clin Trials 3:149, 1982.
3. Amberson JB Jr, McMahon BT, Pinner M: A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc 24:401-435, 1931.
4. American Bible Society: The Holy Bible: Old and New Testaments. King James Version (1611), New York, 1816.
5. Anderson LK, Hendershot RA, Schoolmaker RC: Self-checking digit concepts. J Systems Management 25:36-42, 1974.
6. Anscombe FJ: Sequential estimation. JRSS 40(series B):1-21, 1953.
7. Anscombe FJ: Fixed-sample size analysis of sequential observations. Biometrics 10:89-100, 1954.
8. Anscombe FJ: Sequential medical trials. JASA 58:365-383, 1963.
9. Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: The Anturane Reinfarction Trial. N Engl J Med 298:289-295, 1978.
10. Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302:250-256, 1980.
11. Armitage P: Restricted sequential procedures. Biometrika 44:9-26, 1957.
12. Armitage P: Sequential medical trials: Some comments on FJ Anscombe's paper. JASA 58:384-387, 1963.
13. Armitage P, McPherson CK, Rowe BC: Repeated significance tests on accumulating data. JRSS 132(series A):235-244, 1969.
14. Armitage P: Statistical Methods in Medical Research. John Wiley and Sons, New York, 1971.
15. Armitage P: Sequential Medical Trials (2nd ed.). John Wiley and Sons, New York, 1975.
16. Aspirin Myocardial Infarction Study Research Group: Aspirin Myocardial Infarction Study: Design, Methods, and Baseline Results. Publ. no. 80-2106, National Heart, Lung, and Blood Institute, Bethesda, MD, 1980a.
17. Aspirin Myocardial Infarction Study Research Group: A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243:661-669, 1980b.
18. Backstrom CH, Hursh-Cesar G: Survey Research (2nd ed). John Wiley and Sons, New York, 1981.
19. Bailey NTJ: The Mathematical Approach to Biology and Medicine. John Wiley and Sons, New York, 1967.
20. Barker KN: Data collection techniques: Observation. Am J Hosp Pharm 37:1235-1243, 1980.
21. Barnard PJ, Wright P, Wilcox P: Effects of response instructions and question style on the ease of completing forms. J Occup Psychol 52:209-226, 1979.
22. Baron J: The life of Edward Jenner: With illustrations of his doctrines and selections from his correspondence (book review). Br Foreign Med Rev 6:477-497, 1838.
23. Bayes T: An essay towards solving a problem in the doctrine of chances (reproduced in Biometrika 45:296-315, 1958). Philos Trans Roy Soc Lond 53:370-418, 1763.
24. Beatty WK: Searching the literature and computerized services in medicine: Guides and methods for the clinician. Ann Intern Med 91:326-332, 1979.
25. Beeson PB, McDermott W, Wyndgaarden JB (editors): Cecil's Textbook of Medicine (15th ed). WB Saunders Co, Philadelphia, 1979.
26. Begg CB, Iglewicz B: A treatment allocation procedure for sequential clinical trials. Biometrics 36:81-90, 1980.
27. Bégin G, Boivin M, Bellerose J: Sensitive data collection through the random response technique: Some improvements. J Psychol 101:53-65, 1979.
28. Bégin G, Boivin M: Comparison of data gathered on sensitive questions via direct questionnaire, randomized response technique, and a project method. Psychol Rep 47:743-750, 1980.
29. Bégun JM, Gabriel KR: Closure of the Newman-Keuls multiple comparisons procedure. JASA 76:241-245, 1981.
30. Beta Blocker Heart Attack Trial Research Group: Beta Blocker Heart Attack Trial: Design features. Controlled Clin Trials 2:275-285, 1981.
31. Bishop GF, Oldendick RW, Tuchfarber AJ: Effects of presenting one versus two sides of an issue in survey questions. Public Opinion Quart 46:69-85, 1982.
32. Boston Globe (The): Data changed to put patients in cancer test. June 30, 1980a.
33. Boston Globe (The): Research staff feared for patient's welfare. July 1, 1980b.
34. Boston Globe (The): Passing the buck. July 2, 1980c.
35. Boston Globe (The): MD under fire gets new grant. July 3, 1980d.
36. Boston Sunday Globe: Cancer research data falsified; Boston project collapses. June 29, 1980.
37. Box JF: R. A. Fisher and the design of experiments, 1922-1926. Am Statistician 34:1-7, 1980.
38. Brandt AM: Racism and research: The case of the Tuskegee Syphilis Study. Hastings Center Report 8:21-29, Dec, 1978.
39. Braunwald E: Coronary-artery surgery at the crossroads. N Engl J Med 297:661-663, 1977.
40. Breslow NE, Day NE: Statistical Methods in Cancer Research (vol 1, pg 93). International Agency for Research on Cancer, Lyon, 1980.
41. Bross I: Sequential medical plans. Biometrics 8:188-205, 1952.
42. Bross IDJ: Laetrile. N Engl J Med 307:118, 1982.
43. Brown BW Jr, Hollander M: Statistics: A Biomedical Introduction. John Wiley and Sons, New York, 1977.
44. Brown BW Jr: Designing for cancer clinical trials: Selection of prognostic factors. Cancer Treat Rep 64:499-502, 1980.
45. Brown BW Jr: Comments on the Dupont manuscript. Controlled Clin Trials 4:13-17, 1983.
46. Bryan LS Jr: Bloodletting in American medicine, 1830-1892. Bull Hist Med 38:516-529, 1964.
47. Bull JP: The historical development of clinical therapeutic trials. J Chronic Dis 10:218-248, 1959.
48. Bulpitt CJ: Randomised Controlled Clinical Trials. Martinus Nijhoff Publishers, London, 1983.
49. Burton BT, Hirschman GH: Demographic analysis: End-stage renal disease and its treatment in the United States. Clin Nephrol 11:47-51, 1979a.
50. Burton BT, Hirschman GH: Treatment trends of end stage renal disease in the United States. Artif Organs 3(suppl):29-33, 1979b.
51. Buyse ME, Staquet MJ, Sylvester RJ (editors): Cancer Clinical Trials: Methods and Practices. Oxford University Press, Oxford, 1984.
52. C. Canner PL: Monitoring clinical trials data for evidence of adverse or beneficial treatment effects (in Essais Controles Multicentres: Principles et Problemes, edited by JP Boissel, CR Klimt). Institut National de la Sante et de la Recherche Medicale (INSERM) 76:131-149, 1977a.
53. Canner PL: Monitoring treatment differences in long-term clinical trials. Biometrics 33:603-615, 1977b.
54. Canner PL: Comment on "Statistical inference from clinical trials: Choosing the right p value." Controlled Clin Trials 4:13-17, 1983a.
55. Canner PL: Further comment on "Statistical inference from clinical trials: Choosing the right p value." Controlled Clin Trials 4:35, 1983b.
56. Canner PL, Krol WF, Forman SA: External quality control programs. Controlled Clin Trials 4:441-466, 1983c.
57. Carleton RA, Sanders CA, Burack WR: Heparin administration after acute myocardial infarction. N Engl J Med 263:1002-1005, 1960.
58. Casagrande JT, Pike MC, Smith PG: The power function of the "exact" test for comparing two binomial distributions. Appl Statist 27:176-180, 1978.
59. Cascinelli N, Davis HL Jr, Flamant R, Kenis Y, Lalanne CM, Muggia FM, Rozencweig M, Staquet MJ, Veronesi U: Methods and Impact of Controlled Therapeutic Trials in Cancer (part II). Union Internationale Contre le Cancer Report Series (vol 59), Geneva, 1981.
60. Cassel GH, Ferris FL III: Site visits in a multi-center ophthalmic clinical trial. Controlled Clin Trials 5:251-262, 1984.
61. Chalmers TC, Block JB, Lee S: Controlled studies in clinical cancer research. N Engl J Med 287:75-78, 1972.
62. Chalmers TC: The impact of controlled trials on the practice of medicine. Mt Sinai J Med 41:753-759, 1974.
63. Chalmers TC: Randomization of the first patient. Med Clin North Am 59:1035-1038, 1975.
64. Chalmers TC, Matta RJ, Smith H Jr, Kunzler A: Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 297:1091-1096, 1977.
65. Chalmers TC, Silverman B, Shareck EP, Ambroz A, Schroeder B, Smith H Jr: Randomized control trials in gastroenterology with particular attention to duodenal ulcer (in Report to the Congress of the United States of the National Commission on Digestive Diseases, Vol IV: Reports of the Workgroups: Part 2B: Subcommittee on Research-Targeted and Non-Directed, pp. 223-255). Publ no. NIH 79-1885, National Institute of Arthritis, Metabolism, and Digestive Diseases, Bethesda, Md, 1978.
66. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A: A method for assessing the quality of a randomized control trial. Controlled Clin Trials 2:31-49, 1981.
67. Chalmers TC: Informed consent, clinical research and the practice of medicine. Trans Am Clin Climatol Assoc 94:204-212, 1982a.
68. Chalmers TC: A potpourri of RCT topics. Controlled Clin Trials 3:285-298, 1982b.
69. Chandor A: The Facts on File Dictionary of Microcomputers. Facts on File, Inc, New York, 1981.
70. Charen T: MEDLARS Indexing Manual. No. PB 271-306, National Technical Information Service, Springfield, Va. 1977.
71. Chlebowski RT, Weiner JM, Ryden VMJ, Bateman JR: Factors influencing the interim interpretation of a breast cancer trial: Danger of achieving the "expected" result. Controlled Clin Trials 2:123-132, 1981.
72. Christiansen I, Iverson K, Skouby AP: Benefits obtained by the introduction of a coronary care unit: A comparative study. Acta Med Scand 189:285-291, 1971.
73. Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA: An evaluation of internal-mammary-artery ligation by a double-blind technic. N Engl J Med 260:1115-1118, 1959.
74. Cocco AE, Cocco DV: A survey of cimetidine prescribing. N Engl J Med 304:1281, 1981.
75. Cochran WG: Some methods of strengthening the common X2 tests. Biometrics 10:417-451, 1954.
76. Cochran WG, Cox GM: Experimental Designs (2nd ed). John Wiley and Sons, Inc, New York, 1957.
77. Collen MF, Cutler JL, Siegelaub AB, Cella RL: Reliability of a self-administered medical questionnaire. Arch Intern Med 123:664-681, 1969.
78. Collins JF, Bingham SF, Weiss DG, Williford WO, Kuhn RM: Some adaptive strategies for inadequate sample acquisition in Veterans Administration Cooperative Clinical Trials. Controlled Clin Trials 1:227-248, 1980.
79. Colsky J: Clinical investigator: The clinical investigator and evaluaion of new drugs. Am J Hosp Pharm 20:517-519, 1963.
80. Colton T: A model for selecting one of two medical treatments. JASA 58:388-400, 1963.
81. Commission on Professional and Hospital Activities: Diabetes mellitus: Use of oral antidiabetics. PAS Reporter 10:263, Nov 24, 1972.
82. Commission on Professional and Hospital Activities: Hospital Record Study:1969-1975. Joint publications of CPHA and IMS America, Ltd, Ann Arbor, Mich, 1976.
83. Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents: Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. JAMA 231:583-608, 1975.
84. Committee on Drugs: Unapproved use of approved drugs: The physician, the package insert, and the FDA. Pediatrics 62:262-264, 1978.
85. Committee on Lipoproteins and Atherosclerosis Technical Group and the Committee on Lipoproteins and Atherosclerosis of the National Advisory Heart Council: Evaluation of serum lipoprotein and cholesterol measurements as predictors of clinical complications of atherosclerosis: Report of a cooperative study of lipoproteins and atherosclerosis. Circulation 14:691-741, 1956.
86. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: I. Design and Methods (in two parts). Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, March, 1979a.
87. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: II. RFPs for Coordinating Centers: A Content Evaluation. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, March, 1979b.
88. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: IV. Terminology. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, Aug, 1979c.
89. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: VI. Phases of a Multicenter Trial. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, Sept, 1979d.
90. Coordinating Center Models Project Research Group: Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: XIV. Enhancement of Methodological Research in the Field of Clinical Trials. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, Sept, 1979e.
91. Cornfield J: Principles of research. Am J Ment Defic 64:240-252, 1959.
92. Cornfield J: A Bayesian test of some classical hypotheses-With applications to sequential clinical trials. JASA 61:577-594, 1966a.
93. Cornfield J: Sequential trials, sequential analysis and the likelihood principle. Am Statistician 20:18-23, 1966b.
94. Cornfield J: The Bayesian outlook and its application (including discussion by S Geisser, HO Hartley, O Kempthorne, H Rubin). Biometrics 25:617-657, 1969.
95. Cornfield J: The University Group Diabetes Program: A further statistical analysis of the mortality findings. JAMA 217:1676-1687, 1971.
96. Cornfield J: Design of clinical trials (pp 303-306 in Research Status of Spinal Manipulative Therapy, M Goldstein, editor). Monograph no. 15, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Md. 1975.
97. Cornfield J: Recent methodological contributions to clinical trials. Am J Epidemiol 104:408-421, 1976.
98. Coronary Artery Surgery Study Research Group: National Heart, Lung, and Blood Institute Coronary Artery Surgery Study: A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography (edited by T Killip, LD Fisher, MB Mock). Circulation 63(suppl I):I-1-I-81, 1981.
99. Coronary Artery Surgery Study Research Group: Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery: Survival data. Circulation 68:939-950, 1983.
100. Coronary Artery Surgery Study Research Group: Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery. Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. J Am Coll Cardiol 3:114-128, 1984.
101. Coronary Drug Project Research Group: Coronary Drug Project Data and Safety Monitoring Report. PL Canner, University of Maryland School of Medicine, Baltimore, Feb 1, 1970a.
102. Coronary Drug Project Research Group: The Coronary Drug Project: Initial findings leading to modification of its research protocol. JAMA 214:1303-1313, 1970b.
103. Coronary Drug Project Research Group: The Coronary Drug Project: Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 220:996-1008, 1972.
104. Coronary Drug Project Research Group: The Coronary Drug Project: Design, methods, and baseline results. Circulation 47(suppl I):I-1-I-50, 1973a.
105. Coronary Drug Project Research Group: The Coronary Drug Project: Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 226:652-657, 1973b.
106. Coronary Drug Project Research Group: Factors influencing long-term prognosis after recovery from myocardial infarction-Three year findings of the Coronary Drug Project. J Chronic Dis 27:267-285, 1974.
107. Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975.
108. Coronary Drug Project Research Group: Aspirin in coronary heart disease. J Chronic Dis 29:625-642, 1976.
109. Coronary Drug Project Research Group: Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study. Controlled Clin Trials 1:363-376, 1981.
110. Cox DR: The regression analysis of binary sequences. JRSS 20(series B): 215-242, 1958.
111. Cox DR: Regression models and life tables (including discussion). JRSS 34(series B):187-220, 1972.
112. Cox DR, Hinkley DV: Theoretical Statistics. Chapman and Hall, London, 1974.
113. Creighton C: A History of Epidemics in Britain: From the Extinction of Plague to the Present Time (vol II). The University Press, Cambridge, 1894.
114. Crombie AC: Avicenna's influence on the medieval scientific tradition (pp 84-107) in Avicenna: Scientist and Philosopher, edited by GM Wickens). Luzac and Co, Ltd, London, 1952.
115. Crout JR: Controlled trials: Requirements in the Food, Drug and Cosmetic Act of 1938. National Institutes of Health, Bethesda, MD. Presented at the Society for Clinical Trials Annual Meeting, Pittsburgh, May 3, 1982.
116. Cupples LA, Heeren T, Schatzkin A, Colton T: Multiple testing of hypotheses in comparing two groups (review). Ann Intern Med 100:122-129, 1984.
117. Curran WJ, Shapiro ED: Law, Medicine, and Forensic Science (2nd ed). Little, Brown and Co, Boston, 1970.
118. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chronic Dis 8:699-712, 1958.
119. D. Hawkins HC: Multiple comparisons misused: Why so frequently used in responsecurve studies (commentary)? Biometrics 39:789-790. 1983.
120. Day HW: Effectiveness of an intensive coronary care area. Am J Cardiol 15:51-54, 1965.
121. deAlmeida DJW, Cameron WR, Condie R, Deering RB, Fitzgerald RB, Joannou P, Johnston EM, Munro DF, Smith AGL, Valle-Jones JC: The treatment of dyspepsia in general practice: A multicenter trial. Practitioner 224:105-107, 1980.
122. DeBakey ME, Lawrie GM: Aortocoronary-artery bypass: Assessment after 13 years. JAMA 239:837-859, 1978.
123. DeMets DL, Ware JH: Group sequential methods for clinical trials with a onesided hypothesis. Biometrika 67:651-660, 1980.
124. Department of Health, Education and Welfare: General Provisions for Negotiated Cost-Reimbursement Type Contract with Educational Institutions. HEW-315 (rev 7/76), Washington, 1976.
125. Department of Health, Education and Welfare: The Negotiated Contracting Process: A Guide for Project Officers. Washington, Oct, 1977.
126. Department of Health and Human Services: Administration of Grants: Federal Regulations, Title 45, Part 74. Washington, June 9, 1981.
127. Department of Health and Human Services: Health Care Financing Program Statistics: The Medicare and Medicaid Data Book, 1981. Publ no. 03128, Health Care Financing Administration, Office of Research and Demonstrations, Baltimore, April, 1982a.
128. Department of Health and Human Services: Public Health Service Grants Policy Statement. Publ no. (OASH) 82-50,000 (rev), Washington, Dec 1, 1982b.
129. Devan WJ, Brown MB (editors): Biomedical Computer Programs, P-Series. University of California Press, Los Angeles, Calif, 1979.
130. Diabetic Retinopathy Study Research Group: Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383-396, 1976.
131. Diabetic Retinopathy Study Research Group: Photccoagulation treatment of proliferative diabetic retinopathy: The second report of diabetic retinopathy study findings. Ophthalmology 85:82-106, 1978.
132. Diabetic Retinopathy Study Research Group: Diabetic Retinopathy Study:Report 6. Design, methods, and baseline results. Invest Ophthalmol Vis Sci 21:149-209, 1981.
133. Diehl HS, Baker AB, Cowan DW: Cold vaccines: An evaluation based on a controlled study. JAMA 111:1168-1173, 1938.
134. Dimond EG, Kittle CF, Crockett JE: Comparison of internal mammary artery ligation and sham operation for angina pectoris. Am J Cardiol 5:483-486, 1960.
135. Dixon WJ (editor): BMDP Statistical Software (1981 ed). University of California Press, Los Angeles, 1981.
136. Donaldson N, Donaldson B: How Did They Die? St. Martins Press, Inc, New York, 1980.
137. Draper N, Smith H: Applied Regression Analysis (2nd ed). John Wiley and Sons, New York, 1966.
138. Drummond JC, Wilbraham A: The Englishman's Food: A History of Five Centuries of English Diet. Jonathan Cape, London, 1940.
139. Duncan DB: Multiple range and multiple F tests. Biometrics 11:1-42, 1955.
140. Duncan DB: t tests and intervals for comparisons suggested by the data. Biometrics 31:339-359, 1975.
141. Duncan DB, Godbold JH: Approximate k-ratio t tests for differences between unequally replicated treatments. Biometrics 35:749-756, 1979.
142. Duncan DB, Brandt L: Adaptive t tests for multiple comparisons. Biometrics 39:787-794, 1983a.
143. Duncan DB, Dixon DO: k-ratio t tests, t intervals, and point estimates for multiple comparisons. Encyclopedia of Statistical Sciences (S Kotz, NL Johnson, CB Read, editors, vol 4, pp 403-410). John Wiley and Sons, New York, 1983b.
144. Duncan WJ: Mail questionnaires in survey research: A review of response inducement techniques. J Management 5:39-55, 1979.
145. Duncum BM: The Development of Inhalation Anaesthesia-With Special Reference to the Years 1846-1900. Oxford University Press, London, 1947.
146. Dunnett CW: A multiple comparison procedure for comparing several treatments with a control. JASA 50:1096-1121, 1955.
147. Dunnett CW: New tables for multiple comparisons with a control. Biometrics 20:482-491, 1964.
148. Dupont WD: Sequential stopping rules and sequential adjusted p values: Does one require the other? Controlled Clin Trials 4:3-10, 1983a.
149. Dupont WD: Rejoinder: Statistical inference from trials with sequential stopping rules. Controlled Clin Trials 4:27-33, 1983b.
150. E. Early Treatment of Diabetic Retinopathy Study Research Group: Manual of Operations. National Eye Institute, Bethesda, Md, 1982.
151. Edvardsson B: Effect of reversal of response scales in a questionnaire. Percept Mot Skills 50:1125-1126, 1980.
152. Efron B: Forcing a sequential experiment to be balanced. Biometrika 58:403-417, 1971.
153. Elandt-Johnson RC, Johnson NL: Survival Models and Data Analysis. John Wiley and Sons, New York, 1980.
154. Elliott J: A medical pioneer: John Haygarth of Chester. Br Med J 1:235-242, 1913.
155. Erickson SH, Bergman JJ, Schneeweiss R, Cherkin DC: The use of drugs for unlabeled indications. JAMA 243:1543-1546, 1980.
156. Ethics Advisory Board of the Department of Health and Human Services:The Request of the National Institutes of Health for a Limited Exemption from the Freedom of Information Act. Department of Health and Human Services, Washington, 1980.
157. European Coronary Surgery Study Group: Coronary bypass surgery in stable angina pectoris: Survival at two years. Lancet 1:889-893, 1979.
158. European Coronary Surgery Study Group: Prospective randomised study of coronary artery bypass surgery in stable angina pectoris: Second interim report. Lancet 2:491-495, 1980.
159. European Coronary Surgery Study Group: Prospective randomized study of coronary artery bypass surgery in stable angina pectoris: A progress report on survival. Circulation 65(suppl II):II-67-II-71, 1982a.
160. European Coronary Surgery Study Group: Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 2:1173-1180, 1982b.
161. Feinstein AR: Clinical biostatistics: VII. An analytic appraisal of the University Group Diabetes Program (UGDP) study. Clin Pharmacol Ther 12:167-191, 1971.
162. Fellegi IP, Sunter A: A theory for record linkage. JASA 64:1183-1210, 1969.
163. Feller W: An Introduction to Probability Theory and Its Applications (vol 1, 3rd ed). John Wiley and Sons, New York, 1968.
164. Fibiger J: Om serumbehandlung af difteri. Hospitalstidende 6:309-325, 1898.
165. Finkel MJ: The development of orphan products. N Engl J Med 307:963-964, 1982.
166. Finney HC: Improving the reliability of retrospective survey measures: Results of a longitudinal field survey. Evaluation Rev 5:207-229, 1981.
167. Fisher RA, MacKenzie WA: Studies in crop variation: II. The manurial response of different potato varieties. J Agric Sci 13:311-320, 1923.
168. Fisher RA: The arrangements of field experiments. J Ministry Agric Great Britain 33:503-513, 1926.
169. Fisher RA: Statistical Methods for Research Workers (10th ed). Oliver and Boyd, Edinburgh, 1946.
170. Fisher RA, Yates F: Statistical Tables for Biological, Agricultural and Medical Research (6th ed). Hafner Publishing Company, Inc, New York, 1963.
171. Fisher RA: Statistical Methods and Scientific Inference (3rd ed). Hafner Press, Macmillan Publishing Co, Inc, New York, 1973.
172. Fleiss JL: Statistical Methods for Rates and Proportions (2nd ed). John Wiley and Sons, New York, 1981.
173. Fletcher RH, Fletcher SW, Wagner EH: Clinical Epidemiology: The Essentials. Williams and Wilkins, Baltimore, 1982.
174. Food and Drug Administration: Procedural and interpretative regulations:Investigational use. Federal Register 28:179-182, Jan 8, 1963.
175. Food and Drug Administration: Hearing procedure for refusal or withdrawal of approval of New Drug Applications and for issuance, amendment, or repeal of Antibiotic Drug Regulations: Interpretative description of adequate and well controlled clinical investigations. Federal Register 34:14596-14598, Sept 19, 1969a.
176. Food and Drug Administration: Novobiocin-tetracycline combination drugs:Calcium novobiocin-sulfamethizole tablets. Final order repealing regulations and working certificates. Federal Register 34:14598-14599, Sept 19, 1969b.
177. Food and Drug Administration: Hearing requests on refusal or withdrawal of New Drug Applications and issuance, amendment or repeal of Antibiotic Drug Regulations and describing scientific content of adequate and well-controlled clinical investigations. Federal Register 35:3073-3074, Feb 17, 1970a.
178. Food and Drug Administration: Hearing regulations and regulations describing scientific content of adequate and well-controlled clinical investigations. Federal Register 35:7250-7253, May 8, 1970b.
179. Food and Drug Administration: Oral hypoglycemic agents: Diabetes prescribing information. FDA Current Drug Information, Oct, 1970c.
180. Food and Drug Administration: Oral hypoglycemic agents. FDA Drug Bull, June 23, 1971.
181. Food and Drug Administration: Oral hypoglycemic drug labeling. FDA Drug Bull, May, 1972a.
182. Food and Drug Administration: DESI Who? FDA Consumer, Oct, 1972b.
183. Food and Drug Administration: Drug labeling: Failure to reveal material facts; labeling of oral hypoglycemic drugs. Federal Register 40:28582-28595, July 7, 1975.
184. Food and Drug Administration: Phenformin: New labeling and possible removal from the market. FDA Drug Bull 7:6-7, May-July, 1977a.
185. Food and Drug Administration: HEW Secretary suspends general marketing of phenformin. FDA Drug Bull 7:14-16, Aug, 1977b.
186. Food and Drug Administration: General Considerations for the Clinical Evaluation of Drugs. Publ no. HEW (FDA) 77-3040, Rockville, Md, Sept, 1977c.
187. Food and Drug Administration: Status of withdrawal of phenformin. FDA Drug Bull 7:19-20, Sept-Oct, 1977d.
188. Food and Drug Administration: Oral hypoglycemic drugs: Availability of agency analysis and reopening of comment period on proposed labeling requirements. Federal Register 43:52732-52734, Nov 14, 1978.
189. Food and Drug Administration: Medical devices: Procedures for Investigational Device Exemptions. Federal Register 45:3732-3759, Jan 18, 1980.
190. Food and Drug Administration: Clinical Testing for Safe and Effective Drugs. Investigational Drug Procedures. HHS publ no. (FDA) 74-3015, Rockville, MD, 1981.
191. Food and Drug Administration: Regulatory Requirements for Medical Devices: A Workshop Manual. HHS publ no. (FDA) 83-4165, Rockville, Md, June, 1983.
192. Food and Drug Administration: Guideline Labeling for Oral Hypoglycemic Drugs of the Sulfonylurea Class. Docket no. 83D-0304, Rockville, Md, March 16, 1984a.
193. Food and Drug Administration: Labeling of oral hypoglycemic drugs of the sulfonylurea class. Federal Register 49:14303-14331, April 11, 1984b.
194. Food and Drug Administration: Oral hypoglycemic drug products: Availability of guideline labeling. Federal Register 49:14441-14442, April 11, 1984c.
195. Food and Nutrition Board: Toward Healthful Diets. National Academy of Science, Washington, May 28, 1980.
196. Francis T, Korns RF, Voight RB, Boisen M, Hemphill FM, Napier JA, Tolchinsky E: An evaluation of the 1954 poliomyelitis vaccine trial: Summary report. Am J Public Health 45(part II, May suppl): 1-51, 1955.
197. Fredrickson DS: The field trial: Some thoughts on the indispensable ordeal. Bull NY Acad Med 44:985-993, 1968.
198. Freedman LS, White SJ: On the use of Pocock and Simon's method for balancing treatment numbers and prognostic factors in the controlled clinical trial. Biometrics 32:691-694, 1976.
199. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: Survey of 71 "negative" trials. N Engl J Med 299:690-694, 1978.
200. Frenette C, Bégin G: Sensitive data gathering through the random response technique: A validity study. Psychol Rep 45:1001-1002, 1979.
201. Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials. John Wright, PSG Inc, Boston, 1982.
202. G. Gail M, Gart JJ: The determination of sample sizes for use with the exact conditional test in 2x2 comparative trials. Biometrics 29:441-448, 1973.
203. Gail M: Power computations for designing comparative Poisson trials. Biometrics 30:231-237, 1974.
204. Gail M: Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. Controlled Clin Trials 6:112-119, 1985.
205. Galton F: Regression towards mediocrity in hereditary stature. Anthropological Institute 15:246-263, 1886.
206. Garrett HE, Dennis EW, DeBakey ME: Aortocoronary bypass with saphenous vein graft: Seven-year follow-up. JAMA 223:792-794, 1973.
207. Gart JJ: The comparison of proportions: A review of significance tests, confidence intervals and adjustments for stratification. Review Internal Stat lnst 39:148-169, 1971.
208. Gordis L, Naggan L, Tonascia J: Pitfalls in evaluating the impact of coronary care units on mortality from myocardial infarctions. Johns Hopkins Med J 141:287-295, 1977.
209. Grant AP: Sequential trial of isocarboxazid in angina pectoris. Br Med J 1:513-515, 1962.
210. Greenberg BG (chairman): A Report from the Heart Special Project Committee to the National Advisory Heart Council: Organization, Reviews and Administration of Cooperative Studies, May, 1967. Controlled Clin Trials 9:137-148, 1988.
211. Greenhouse SW, Halperin M: Jerome Cornfield: 1912-1979. Controlled Clin Trials 1:75-80, 1980.
212. Greenhouse SW: Discussion on early stopping. Controlled Clin Trials 4:23-25, 1983.
213. Grizzle JE: A note on stratifying versus complete random assignment in clinical trials. Controlled Clin Trials 3:365-368, 1982.
214. Hagans J: The design and methodology of cooperative drug trials. Drug Intell Clin Pharm 8:531-534, 1974.
215. Haggard HW: The Lame, the Halt, and the Blind: The Vital Role of Medicine in the History of Civilization. Harper and Brothers, New York, 1932.
216. Hainline A Jr, Miller DT, Mather A: Role and methods of the central laboratory. Controlled Clin Trials 4:377-387, 1983.
217. Halperin M, Rogot E, Gurian J, Ederer F: Sample sizes for medical trials with special reference to long-term therapy. J Chronic Dis 21:13-24, 1968.
218. Hamilton MP: Role of an ethicist in the conduct of clinical trials in the United States. Controlled Clin Trials 1:411-420, 1981.
219. Harville DA: Experimental randomization: Who needs it? Am Statistician 29:27-31, 1975.
220. Haseman JK: Exact sample sizes for use with the Fisher-Irwin test for 2x2 tables. Biometrics 34:106-109, 1978.
221. Hauck WW: Letter to the editor concerning random number generators. Controlled Clin Trials 3:73, 1982.
222. Haupt BJ: Deliveries in short-stay hospitals: United States, 1980. Vital and Health Statistics of the National Center for Health Statistics, no. 83, Hyattsville, Md, Oct 8, 1982.
223. Haverkamp AD, Thompson HE, McFee JG, Cetrulo C: The evaluation of continuous fetal heart rate monitoring in high-risk pregnancy. Am J Obstet Gynecol 125:310-320, 1976.
224. Haverkamp AD, Orleans M, Langendoerfer S, McFee J, Murphy J, Thompson HE: A controlled trial of the differential effects of intrapartum fetal monitoring. Am J Obstet Gynecol 134:399-412, 1979.
225. Hawkins BS, Canner PL: Impact of closeout on operations at two coordinating centers. The Johns Hopkins University, Baltimore. Presented at the 4th Annual Symposium on Coordinating Clinical Trials, Arlington, Va, May 25-26, 1978.
226. Hawkins BS: Staffing the coordinating center: Who is minding the data? (in Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: XVI. CCMP Manuscripts Presented at the Annual Symposia on Coordinating Clinical Trials, pp. 155-187). Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, June, 1979.
227. Hawkins BS: Perusing the literature. Controlled Clin Trials 1:71-74, 181-185, 269-274, 1980.
228. Hawkins BS: Perusing the literature. Controlled Clin Trials 2:51-57, 257-265, 327-333, 1981.
229. Hawkins BS: Perusing the literature. Controlled Clin Trials 3:371-383, 1982.
230. Hawkins BS: Perusing the literature. Controlled Clin Trials 4:75-86, 239-253, 1983.
231. Haygarth J: Of the Imagination, as a Cause and as a Cure of Disorders of the Body: Exemplified by Fictitious Tractors, and Epidemical Convulsions. R Cruttwell, Bath, 1800.
232. Helsing KJ, Comstock GW: Response variation and location of questions within a questionnaire. Internat J Epidemiol 5:125-130, 1976.
233. Hill AB: Statistical Methods in Clinical and Preventive Medicine. Oxford University Press, New York, 1962.
234. Hill AB: Principles of Medical Statistics (9th ed). Oxford University Press, New York, 1971.
235. Hill JD, Holdstock G, Hampton JR: Comparison of mortality of patients with heart attacks admitted to a coronary care unit and an ordinary medical ward. Br Med J 2:81-83, 1977.
236. Hill JD, Hampton JR, Mitchell JRA: A randomised trial of home-versus-hospital management for patients with suspected myocardial infarction. Lancet 1:837-841, 1978.
237. Himmelfarb S, Edgell SE: Additive constants model: A randomized response technique for eliminating evasiveness to quantitative response questions. Psychol Bull 87:525-530, 1980.
238. Hochstim JR, Renne KS: Reliability of response in a sociomedical population study. Public Opinion Quart 35:69-79, 1971.
239. Holland WW, Ashford JR, Colley JRT, Morgan DC, Pearson NJ: A comparison of two respiratory symptoms questionnaires: 1. Methodology and observer variation. Br J Prev Soc Med 20:76-96, 1966.
240. Holman DV: Venesection before Harvey and after. Bull NY Acad Med 31:661-670, 1955.
241. Howard JM, DeMets D, and the BHAT Research Group: How informed is informed consent? The BHAT experience. Controlled Clin Trials 2:287-303, 1981.
242. Hypertension Detection and Follow-Up Program Cooperative Group: Fiveyear findings of the Hypertension Detection and Follow-Up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242:2562-2571, 1979a.
243. Hypertension Detection and Follow-Up Program Cooperative Group:Therapeutic control of blood pressure in the Hypertension Detection and Follow-Up Program. Prev Med 8:2-13, 1979b.
244. I. IMS America, Ltd (Ambler, Pa): Diabetic therapy. National Disease Therapeutic Review 8:7, June, 1977.
245. Ingelfinger JA, Mosteller F, Thibodeau LA, Ware JH: Biostatistics in Clinical Medicine. Macmillan Publishing Co, New York, 1983.
246. International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. Br Med J 284:1766-1770, 1982.
247. J. James G, James RC (editors): Mathematics Dictionary (multilingual ed). D Van Nostrand Company, Inc, Princeton, NJ, 1959.
248. Jenner E: An Inquiry into the Causes and Effects of the Variolae Vaccinae. Sampson Low, London, 1798.
249. Jones JH: Bad Blood: The Tuskegee Syphilis Experiment. The Free Press, New York, 1981.
250. Juhl E, Christensen E, Tygstrup N: The epidemiology of the gastriontestinal randomized clinical trial. N Engl J Med 296:20-22, 1977.
251. K. Kalbfieisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York, 1980.
252. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. JASA 53:457-481, 1958.
253. Keefer CS, Blake FG, Marshall EK Jr, Lockwood JS, Wood WB Jr: Penicillin in the treatment of infections: A report of 500 cases. JAMA 122:1217-1224, 1943.
254. Keen H, Jarrett RJ: The effect of carbohydrate tolerance on plasma lipids and atherosclerosis in man (pp 435-444, 446-449 in Atherosclerosis, RJ Jones, editor). Springer-Verlay, New York, 1970.
255. Keen H: Factors influencing the progress of atherosclerosis in the diabetic. Acta Diabet Lat 8(suppl 1):444-456, 1971.
256. Kelsey FO: Government: The Kefauver-Harris Amendments and investigational drugs. Am J Hosp Pharm 20:515-517, 1963.
257. Kelso IM, Parsons RJ, Lawrence GF, Arora SS, Edmonds DK, Cooke ID:An assessment of continuous fetal heart rate monitoring in labor: A randomized trial. Am J Obstet Gynecol 131:526-532, 1978.
258. Kendall MG, Buckland WR: A Dictionary of Statistical Terms (2nd ed). Hafner Publishing Company, New York, 1960.
259. Kenton C, Scott YB: MEDLINE searching and retrieval. Med Inf 3:225-235, 1978.
260. Kidder LH: Selltiz, Wrightsman and Cook's Research Methods in Social Relations (4th ed). Holt, Rinehart and Winston, New York, 1981.
261. Kilo C, Miller JP, Williamson JR: The achilles heel of the University Group Diabetes Program. JAMA 243:450-457, 1980.
262. King LS: The bloodletting controversy: A study in the scientific method. Bull Hist Med 35:1-13, 1961.
263. Klein E: A Comprehensive Etymological Dictionary of the English Language. Elsevier Scientific Publishing Co, Amsterdam, 1971.
264. Kleinbaum DG, Kupper LL, Chambless LE: Logistic regression analysis of epidemiologic data: Theory and practice. Commun Statist-Theor Meth 11:485-547, 1982.
265. Klimt CR, Canner PL: Terminating a long term clinical trial. Clin Pharmacol Ther 25:641-646, 1979.
266. Klimt CR: Terminating a long-term clinical trial. Controlled Clin Trials 1:319-325, 1981.
267. Knatterud GL: Lessons learned in monitoring for treatment effects in the Diabetic Retinopathy Study (abstract). Am J Epidemiol 106:247, 1977.
268. Knatterud GL: Methods of quality control and of continuous audit procedures for controlled clinical trials. Controlled Clin Trials 1:327-332, 1981.
269. Knatterud GL, Forman SA, Canner PL: Design of data forms. Controlled Clin Trials 4:429-440, 1983.
270. Knox JHM Jr: The medical history of George Washington, his physicians, friends and advisers. Bull Inst Hist Med 1:174-191, 1933.
271. Knox RA: The pill for diabetics. Boston Sunday Globe, Nov 7, 1971.
272. Knuth DE: Seminumerical Algorithms (vol 2 of The Art of Computer Programming). Addison-Wesley Publishing Co, Reading, Mass, 1969.
273. Kolata GB: Controversy over study of diabetes drugs continues for nearly a decade. Science 203:986-990, 1979.
274. Kotz S, Johnson NL, Read CB (editors): Encyclopedia of Statistical Sciences. John Wiley and Sons, New York, 1982.
275. Krol WF: Closing down the study. Controlled Clin Trials 4:505-412, 1983.
276. Kruskal WH, Tanur JM (editors): International Encyclopedia of Statistics (in 2 vols). The Free Press, Macmillan Publishing Co, Inc, New York, 1978.
277. L. Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 2:93-113, 1981.
278. Last JM (editor): A Dictionary of Epidemiology. Oxford University Press, New York, 1983.
279. Layne BH, Thompson DN: Questionnaire page length and return rate. J Soc Psychol 113:291-292, 1981.
280. Ledger RR: Safety of Upjohn's oral antidiabetic drug doubted in study: Firm disputes findings. Wall Street Journal, May 21, 1970.
281. Lee ET: Statistical Methods for Survival Data Analysis. Lifetime Learning Publications, Wadsworth Inc, Belmont, Calif, 1980.
282. Levine J, Guy W, Cleary PA: Therapeutic trials of psychopharmacologic agents:1968-1972 (in Principles and Techniques of Human Research, vol VIII. Psychopharmacological Agents, edited by FG McMahon). Futura Publishing Co, Mt. Kisco, NY, 1974.
283. Levine MM: Informed consent (abstract). Am J Epidemiol 104:350, 1976.
284. Levine RJ, Lebacqz K: Some ethical considerations in clinical trials. Clin Pharmacol Ther 25:728-741, 1979.
285. Levine RJ: Ethics and Regulations of Clinical Research. Urban and Schwarzenberg, Baltimore, 1981.
286. Lieberman GJ, Owen DB: Tables of the Hypergeometric Probability Distribution. Stanford University Press, Stanford, Calif, 1961.
287. Lilienfeld AM: Ceteris paribus: The evolution of the clinical trial. Bull Hist Med 56:1-18, 1982.
288. Lind J: A Treatise of the Scurvy (reprinted in Lind's Treatise on Scurvy, edited by CP Stewart, D Guthrie, Edinburgh University Press, Edinburgh, 1953). Sands, Murray, Cochran, Edinburgh, 1753.
289. Lindley DV: The Role of Randomization in Inference. Report no. M 627, Department of Statistics, Florida State University, Tallahassee, 1982.
290. Lipid Research Clinics Program: Recruitment for clinical trials: The Lipid Research Clinics Coronary Primary Prevention Trial experience: Its implication for future trials (WS Agras, RH Bradford, GD Marshall, editors). Circulation 66 (suppl IV):IV-1-IV-78, 1982.
291. M. Macular Photocoagulation Study Group: Argon laser photocoagulation for senile macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 100:912-918, 1982.
292. Macular Photocoagulation Study Group: Argon laser photocoagulation for ocular histoplas-mosis: Results of a randomized clinical trial. Arch Ophthalmol 101:1347-1357, 1983a.
293. Macular Photocoagulation Study Group: Argon laser photocoagulation for ideopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol 101:1358-1361, 1983b.
294. Macular Photocoagulation Study Group: Changing the protocol: A case report from the Macular Photocoagulation Study. Controlled Clin Trials 5:203-216, 1984.
295. Management Committee of the Australian Therapeutic Trial in Mild Hypertension: The Australian Therapeutic Trial in Mild Hypertension. Lancet 1:1261-1267, 1980.
296. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959.
297. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Reports 50:163-170, 1966.
298. Market Facts, Inc: The Impact of Two Clinical Trials on Physician Knowledge and Practice. Final Report. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, March, 1982.
299. Marks IN, Wright JP, Denyer M, Garisch JAM, Lucke W: Comparison of sucralfate with cimetidine in the short-term treatment of chronic peptic ulcers. S Afr Med J 57:567-573, 1980.
300. Marks RG: Designing a Research Project: The Basics of Biomedical Research Methodology. Lifetime Learning Publications, Wadsworth Inc, Belmont, Calif, 1982.
301. Martin GL, Newman IM: Randomized response: A technique for improving the validity of self-reported health behaviors. J Sch Health 52:222-226, 1982.
302. Mather HG, Pearson NG, Read KLQ, Steed GR, Thorne MG, Jones S, Guerrier CJ, Eraut CD, McHugh PM, Chowdhury NR, Jafary MH, Wallace TJ:Acute myocardial infarction: Home and hospital treatment. Br Med J 3:334-338, 1971.
303. Mather HG, Morgan DC, Pearson NG, Read KLQ, Shaw DB, Steed GR, Thorne MG, Lawrence CJ, Riley IS: Myocardial infarction: A comparison between home and hospital care for patients. Br Med J 1:925-929, 1976.
304. Matts JP, Long JM, and POSCH Group: Modeling recruitment from the population to the randomized patient (abstract). Controlled Clin Trials 1:169, 1980.
305. McCarn DB: MEDLINE: An introduction to on-line searching. J Am Soc Inf Sci 31ASI-192, 1980.
306. McDill M: Activity analysis of data coordinating centers (in Coordinating Center Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: XVI. CCMP Manuscripts Presented at the Annual Symposia on Coordinating Clinical Trials, pp 105-125). Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, June, 1979.
307. McFarland SG: Effects of question order on survey responses. Public Opinion Quart 45:208-215, 1981.
308. McLaughlin GH: SMOG grading-a new readability formula. J Reading 12:639-646, 1969.
309. Meadows AJ: Dictionary of New Information Technology. Nichols Publishing Co, New York, 1982.
310. Medical Research Council: Clinical trials of new remedies (annotations). Lancet 2:304, 1931.
311. Medical Research Council: Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. Br Med J 2:769-782, 1948.
312. Meier P: Stratification in the design of a clinical trial. Controlled Clin Trials 1:355-361, 1981.
313. Meinert CL: Quality assurance in clinical trials. Institut National de la Santé et de la Recherche Medicale (INSERM) 76:123-130, 1977.
314. Meinert CL: Cost profiles of data coordinating centers (in Coordinating Center Models Project: A study of Coordinating Centers in Multicenter Clinical Trials: XVI. CCMP Manuscripts Presented at the Annual Symposia on Coordinating Clinical Trials, pp. 127-153). Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, June 1979a.
315. Meinert CL: Recommendations and comments on the organization of multicenter trials (in Coordinating Centers Models Project: A Study of Coordinating Centers in Multicenter Clinical Trials: XVI. CCMP Manuscripts Presented at the Annual Symposia on Coordinating Clinical Trials, pp 257-284). Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, June 1979b.
316. Meinert CL: Terminology-A plea for standardization (editorial). Controlled Clin Trials 1:97-99, 1980a.
317. Meinert CL: Clinical trials and data integrity (editorial). Controlled Clin Trials 1:189-192, 1980b.
318. Meinert CL: Organization of multicenter clinical trials. Controlled Clin Trials 1:305-312, 1981.
319. Meinert CL: Funding for clinical trials. Controlled Clin Trials 3:165-171, 1982.
320. Meinert CL, Heinz EC, Forman SA: Role and methods of the coordinating center. Controlled Clin Trials 4:355-375, 1983.
321. Meinert CL, Tonascia S, Higgins K: Content of reports on clinical trials: A critical review. Controlled Clin Trials 5:328-347, 1984.
322. Miller RG Jr: Simultaneous Statistical Inference. McGraw-Hill Book Company, New York, 1966.
323. Miller RG Jr: Developments in multiple comparisons: 1966-1976. JASA 72:779-788, 1977.
324. Milman N, Scheibel J, Jessen O: Lysine prophylaxis in recurrent herpes simplex labialis: A double-blind, controlled crossover study. Acta Derm Venereol 60:85-87, 1980.
325. Milne JS, Williamson J: Comparison of teaching machine with an observer in detection of angina pectoris by questionnaire. Br J Prev Soc Med 25:105-108, 1971.
326. Mintz M: Antidiabetes pill held causing early death. The Washington Post, May 22, 1970a.
327. Mintz M: Discovery of diabetes drug's perils stirs doubts over short-term tests. The Washington Post, June 8, 1970b.
328. Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP: A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306:201-206, 1982.
329. Montgomery B: Abuses of Freedom of Information Act. JAMA 242:1007-1009, 1979.
330. Morgenstern H, Bursic ES: A method for using epidemiologic data to estimate the potential impact of an intervention on the health status of a target population. J Community Health 7:292-309, 1982.
331. Morris RA, Sales BD, Berman JJ: Research and the Freedom of Information Act. American Psychol 36:819-826, 1981.
332. Morris W (editor): The American Heritage Dictionary of the English Language. American Heritage Publishing Co, Inc and Houghton Mifflin Co, New York, 1973.
333. Moses LE, Oakford RY: Tables of Random Permutations. Stanford University Press, Stanford, Calif, 1963.
334. Mosteller F, Gilbert JP, McPeek B: Reporting standards and research strategies for controlled trials: Agenda for the editor. Controlled Clin Trials 1:37-58, 1980.
335. Mount FW, Ferebee SH: Control study of comparative efficacy of isoniazid, streptomycinisoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: I. Report on twelve-week observations on 526 patients. Am Rev Tuberc 66:632-635, 1952.
336. Mount FW, Ferebee SH: Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: II. Report on twenty-week observations on 390 patients with streptomycin-susceptible infections. Am Rev Tuberc 67:108-113, 1953a.
337. Mount FW, Ferebee SH: Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: III. Report on twenty-eight-week observations on 649 patients with streptomycin-susceptible infections. Am Rev Tuberc 67:539-543, 1953b.
338. Multicenter Investigation of the Limitation of Infarct Size Research Group: Organization and Bylaws. Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md, 1983.
339. Multiple Risk Factor Intervention Trial Research Group: Statistical design considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis 30:261-275, 1977.
340. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 248:1465-1477, 1982.
341. Mundy GR, Fleckenstein L, Mazzullo JM, Sundaresan PR, Weintraub M, Lasagna L: Current medical practice and the Food and Drug Administration: Some evidence for the existing gap. JAMA 229:1744-1748, 1974.
342. Murphy ML, Hultgren HN, Detre K, Thomsen J, Takaro T, and participants of the Veterans Administration Cooperative Study: Treatment of chronic stable angina: A preliminary report of survival data of the randomized Veterans Administration Cooperative Study. N Engl J Med 297:621-627, 1977.
343. Murray JAH, Bradley H, Craigie WA, Onions CT (editors): The Oxford English Dictionary: A New English Dictionary on Historical Principles (in 13 vols). Clarendon Press, Oxford, 1970.
344. N. National Cancer Institute: Compilation of Experimental Cancer Therapy Protocol Summaries (7th ed). Bethesda, Md, 1983.
345. National Center for Health Statistics: National Death Index: User's Manual. HHS publ no. (PHS) 81-1148, Hyattsville, Md, 1981.
346. National Cooperative Gallstone Study Group: Design and methodological considerations in the National Cooperative Gallstone Study: A multicenter clinical trial. Controlled Clin Trials 2:177-299, 1981a.
347. National Cooperative Gallstone Study Group: Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study: A controlled trial of efficacy and safety. Ann Intern Med 95:257-282, 1981b.
348. National Cooperative Gallstone Study Group: Major issues in the organization and implementation of the National Cooperative Gallstone Study (NCGS). Controlled Clin Trials 5:1-12, 1984.
349. National Diet-Heart Study Research Group: The National Diet-Heart Study:Final report. Circulation 37(suppl I):I-1-1-428, 1968.
350. National Heart, Lung, and Blood Institute: National Conference on High Blood Pressure Education: Report of Proceedings. Publ no. (NIH) 73-486, Bethesda, Md, 1973.
351. National Institute of Arthritis, Metabolism, and Digestive Diseases:Request for Research Cooperative Agreement Application: Clinical Centers for a Collaborative Clinical Trial on the Relationship Between Blood Glucose Control and Vascular Complications of Insulin-Dependent Diabetes Mellitus. RFA NIAMDD 81-01, Bethesda, Md, 1981a.
352. National Institute of Arthritis, Metabolism, and Digestive Diseases:Request for Proposal: Data Coordinating Center for a Collaborative Clinical Trial on the Relationship Between Blood Glucose Control and Early Vascular Complications of Insulin-Dependent Diabetes Mellitus. RFP NH-NIAMDD 81-9, Bethesda, Md, 1981b.
353. National Institutes of Health: NIH Inventory of Clinical Trials: Fiscal Year 1975 (in two vols). Division of Research Grants, Research Analysis and Evaluation Branch, Bethesda, Md, 1975.
354. National Institutes of Health: NIH Inventory of Clinical Trials: Fiscal Years 1976 through 1979 (unpublished). Data tapes obtained from the Division of Research Grants, Research Analysis and Evaluation Branch, Bethesda, Md, 1980.
355. National Institutes of Health: Basic Data Relating to the National Institutes of Health. Office of Program Planning and Evaluation, and the Division of Research Grants, Bethesda, Md, May 1981a.
356. National Institutes of Health: NIH Almanac. Publ no. 81-5, Division of Public Information, Bethesda, Md, 1981b.
357. National Institutes of Health Clinical Trials Committee (RS Gordon Jr, chairman): Clinical trial activity. NIH Guide for Grants and Contracts 8:29, June 5, 1979.
358. National Library of Medicine: Medical Subject Headings: Index Medicus. NIH publ no. 81-259, Bethesda, Md, 1980.
359. National Library of Medicine: List of Journals Indexed in Index Medicus. NIH publ no. 83-267, Bethesda, Md, 1983.
360. National Research Council: Report of Ad Hoc Committee on Dimethyl Sulfoxide. Division of Medical Sciences, National Academy of Sciences, Washington, 1973.
361. Neyman J, Pearson ES: Joint Statistical Papers. University of California Press, Berkeley, Calif, 1966.
362. Norusis Mj: SPSSx Introductory Statistics Guide. McGraw-Hill Book Co, New York, 1983.
363. O. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979.
364. O'Brien PC: The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics 39:787-788, 1983.
365. Office for Protection from Research Risks: Code of Federal Regulations: Title 45: Public Welfare, Part 46: Protection of Human Subjects. National Institutes of Health, Bethesda, Md, 1983.
366. Office of Technology Assessment: The Impact of Randomized Clinical Trials on Health Policy and Medical Practice: Background Paper. OTA-BP-H-22, United States Congress, Washington, Aug, 1983.
367. Ott WJ: Primary cesarean section: A critical analysis. Obstet Gynecol 58:691-695, 1981.
368. Overton HH: Perceptions of the coordinating center-As viewed by a clinical coordinator. Controlled Clin Trials 1:131-136, 1980.
369. P. Paasikivi J: Long-term tolbutamide treatment after myocardial infarction. Acta Med Scand suppl 507:1-82, 1970.
370. Packard FR: Life and Times of Ambroise Paré, 1510-1590. Paul B Hoeber, New York, 1921.
371. Park WH, Bullowa JGM, Rosenbluth MB: The treatment of lobar pneumonia with refined specific antibacterial serum. JAMA 91:1503-1508, 1928.
372. Patulin Clinical Trials Committee (of the Medical Research Council): Clinical trial of Patulin in the common cold. Lancet 2:373-375, 1944.
373. Payne SL: The Art of Asking Questions. Princeton University Press, Princeton, NJ, 1951.
374. Perry GT, Dunphy JV, Fruin RC, Littman A: Gastric freezing for duodenal ulcer:A double blind study. Gastroenterology 47:6-9, 1964.
375. Persantine Aspirin Reinfarction Study Research Group: Persantine Aspirin Reinfarction Study: Design, methods and baseline results. Circulation 62(suppl II): II-1-11-42, 1980a.
376. Persantine Aspirin Reinfarction Study Research Group: Persantine and aspirin in coronary heart disease. Circulation 62:449-461, 1980b.
377. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612, 1976.
378. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977.
379. Pines WL: A Primer on New Drug Development. Publ no. 1980-311-254/83, Food and Drug Administration, Rockville, Md, 1980.
380. Pitman EJG: Significance tests which may be applied to samples from any populations: III. The analysis of variance test. Biometrika 29:322-335, 1937.
381. Plackett RL: Current trends in statistical inference. JRSS 129 (series A):249-267, 1966.
382. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975.
383. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977.
384. Pocock SJ: Clinical Trials: A Practical Approach. John Wiley and Sons, Chichester, 1983.
385. Presberg J, Timnick L: Federal investigation into heart research project here. St. Louis Globe-Democrat, May 3, 1976.
386. Prout TE, Knatterud GL, Meinert CL: Diabetes drugs: Clinical trial (letter). Science 204:362-363, 1979.
387. R. Rand Corporation (The): A Million Random Digits with 100,000 Normal Deviates. The Free Press, Glencoe, Ill, 1955.
388. Rand LI, Knatterud GL: Certification of clinics and staff in a multicenter clinical trial. University of Maryland, Baltimore. Presented at the Combined Annual Scientific Sessions of the Society for Clinical Trials and the 7th Annual Symposium for Coordinating Clinical Trials, Philadelphia, May 6-8, 1980.
389. Ray AA (editor): SAS User's Guide: Statistics (1982 ed). SAS Institute Inc, Cary, NC, 1982.
390. Relman AS: Publications and promotions for the clinical investigator. Clin Pharmacol Ther 25:673-676, 1979.
391. Relman AS: Closing the books on Laetrile. N Engl J Med 306:236, 1982.
392. Remington RD: Problems of university-based scientists associated with clinical trials. Clin Pharmacol Ther 25:662-665, 1979.
393. Renou P, Chang A, Anderson I, Wood C: Controlled trial of fetal intensive care. Am J Obstet Gynecol 126:470-476, 1976.
394. Research Development Committee, Society for Research and Education in Primary Care Internal Medicine (RH Fletcher, chairman): Clinical research methods:An annotated bibliography. Ann Intern Med 99:419-424, 1983.
395. Rheumatic Fever Working Party of the Medical Research Council of Great Britain and the Subcommittee of Principal Investigators of the American Council of Rheumatic Fever and Congenital Heart Disease, American Heart Association: The evolution of rheumatic heart disease in children: Five year report of a cooperative clinical trial of ACTH, cortisone and aspirin. Circulation 22:503-515, 1960.
396. Robbins H: Some aspects of the sequential design of experiments. Bull Am Mathematics Soc 58:527-535, 1952.
397. Robbins H: A sequential decision problem with finite memory. Proc Natl Acad Sci 42:920-923, 1956.
398. Romm FJ, Hulka BS: Developing criteria for quality of care assessment: Effect of the Delphi technique. Health Serv Res 14:309-312, 1979.
399. Roper FW, Boorkman J: Introduction to Reference Sources in the Health Sciences. Medical Library Association, Inc, Chicago, Ill, 1980.
400. Roth A, Klassen D, Lubin B: Effects of follow-up procedures on survey results. Psychol Rep 47:275-278, 1980.
401. Rothman DJ: Were Tuskegee and Willowbrook "Studies in Nature"? Hastings Center Report 12:5-7, April 1982.
402. Royall RM: Discussion of Dupont's "Statistical inference from clinical trials: Choosing the right p value." Controlled Clin Trials 4:23-25, 1983.
403. S. Sackett DL, Gent M: Controversy in counting and attributing events in clinical trials. N Engl J Med 301:1410-1412, 1979.
404. Sackett DL: The competing objectives of clinical trials. N Engl J Med 303:1059-1060, 1980.
405. Schade RR, Donaldson RM: How physicians use cimetidine: A survey of hospitalized patients and published cases. N Engl J Med 304:1281-1284, 1981.
406. Scheffe H: A method for judging all contrasts in the analysis of variance. Biometrika 40:87-104, 1953.
407. Schlesselman JJ: Case-Control Studies: Design, Conduct, Analysis. Oxford University Press, New York, 1982.
408. Schmeck HM Jr: Scientists wary of diabetic pill: FDA study indicates oral drug may be ineffective. New York Times, May 22, 1970.
409. Schor S: The University Group Diabetes Program: A statistician looks at the mortality results. JAMA 217:1671-1675, 1971.
410. Schriesheim CA: The effect of grouping or randomizing items on leniency response bias. Educat Psychol Measurement 41:401-411, 1981.
411. Schuman SH, Olansky S, Rivers E, Smith CA, Rambo DS: Untreated syphilis in the male Negro: Background and current status of patients in the Tuskegee Study. J Chronic Dis 2:543-558, 1955.
412. Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 20:637-648, 1967.
413. Schwartz TB: The tolbutamide controversy: A personal perspective. Ann Intern Med 75:303-306, 1971.
414. Sciotti H, Sciotti S, Zogbi M (editors): Ubrich's International Periodicals Directory (21st ed, in 2 vols). RR Bowker Co, New York, 1982.
415. Scott DHT, Arthur GR, Scott DB: Haemodynamic changes following buprenorphine and morphine. Anaesthesia 35:957-961, 1980.
416. Seigel D (chairman, editorial committee): A Memorial Symposium in Honor of Jerome Cornfield. Biometrics 38(suppl):1-165, 1982.
417. Seigel D, Milton RC: Further results on a multiple-testing procedure for clinical trials. Biometrics 39:921-928, 1983.
418. Selmer ES: Registration numbers in Norway: Some applied number theory and psychology. JRSS 130(series A):225-231, 1967.
419. Seltzer HS: A summary of critcisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21:976-979, 1972.
420. Shapiro SH, Louis TA (editors): Clinical Trials: Issues and Approaches. Marcel Dekker, Inc, New York, 1983.
421. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE Jr: The Multiple Risk Factor Intervention Trial (MRFIT): II. The development of the protocol. Prev Med 10:402-425, 1981
422. Simon R: Adaptive treatment assignment methods and clinical trials. Biometrics 33:743-749, 1977.
423. Smith CV, Pyke R: The Robbins-Isbell two-armed-bandit problem with finite memory. Ann Math Statistics 36:1375-1386, 1965.
424. Smith TW: Qualifications to generalized absolutes: "Approval of hitting" questions on the GSS. Public Opinion Quart 45:224-230, 1981.
425. Smith WM: Problems in long-term trials. Merck, Sharp and Dohme, West Point, Pa. Presented at the Joint WHO/ISH Meeting on Mild Hypertension, Susona, Japan, Sept, 1978.
426. Smythe M: Record numbering (pp 179-187 in Record Linkage in Medicine, HD Achison, editor). The Williams and Wilkins Co, Baltimore, 1968.
427. Snedecor GW, Cochran WG: Statistical Methods (6th ed). The Iowa State University Press, Ames, Iowa, 1967.
428. Snell, ES, Armitage P: Clinical comparisons of diamorphine and pholcodine as cough suppressants: By a new method of sequential analysis. Lancet 1:860-862, 1957.
429. Society for Clinical Trials, Inc: By Laws. Controlled Clin Trials 1:83-89, 1980.
430. Stallones RA: The effects of the Freedom of Information Act on research. Am J Public Health 72:335-337, 1982.
431. Stokes J, Noren J, Shindell S: Definition of terms and concepts applicable to clinical preventive medicine. J Community Health 8:33-41, 1982.
432. Strauss MB (editor): Familiar Medical Quotations. Little, Brown and Company, Boston, 1968.
433. Stross JK, Harlan WR: The dissemination of new medical information. JAMA 241:2622-2624, 1979.
434. Stross JK, Harlan WR: Dissemination of relevant information on hypertention. JAMA 246:360-362, 1981.
435. Sudman S, Bradburn NM: Asking Questions: A Practical Guide to Questionnaire Design. Jossey-Bass Inc, Publishers, San Francisco, 1983.
436. Sutton HG: Cases of rheumatic fever. Guy's Hosp Rep 11:392-428, 1865.
437. Szklo M: The epidemiologic basis for hypertension control. J Pub Hlth Policy 1:312-327, 1980.
438. T. Taylor SH, Silke B, Ebbutt A, Sutton GC, Prout BJ, Burley DM: A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 307:1293-1301, 1982.
439. Temple R, Pledger GW: Special report: The FDA's critique of the Anturane Reinfarction Trial. N Engl J Med 302:1488-1492, 1980.
440. Thorndike EL, Lorge I: The Teacher's Word Book of 30,000 Words. Columbia University, New York, 1944.
441. Tonascia J: Lecture notes from Epidemiology 2. The Johns Hopkins School of Hygiene and Public Health, Baltimore, 1983.
442. Tucker WB: The evolution of the cooperative studies in the chemotherapy of tuberculosis of the Veterans Administration and Armed Forces of the USA: An account of the evolving education of the physician in clinical pharmacology. Adv Tuberc Res 10:1-68, 1960.
443. Tukey JW: "Quick and dirty methods in statistics." Part II: A simple analysis for standard designs. Proceedings of the 5th Annual Convention of the American Society for Quality Control, pp 189-197, 1951.
444. Tukey JW: Some thoughts on clinical trials, especially problems of multiplicity. Science 198:679-684, 1977.
445. Tuskegee Syphilis Study Ad Hoc Advisory Panel: Final Report of the Tuskegee Syphilis Study Ad Hoc Advisory Panel (47 pages). United States Department of Health, Education, and Welfare, Washington, 1973.
446. Tygstrup N, Lachin JM, Juhl E (editors): The Randomized Clinical Trial and Therapeutic Decisions. Marcel Dekker, Inc, New York, 1982.
447. U. United States Congress (87th): Drug Amendments of 1962, Public Law 87-781, S 1522. Washington, Oct 10, 1962.
448. United States Congress (94th): Medical Device Amendments of 1976, Public Law 94-295, S 510. Washington, May 28, 1976.
449. United States Congress (97th): Small Business Innovation Research Act of 1981 (S 881). Washington, Dec 8, 1981.
450. United States Court of Appeals for the District of Columbia Circuit: Peter H Forsham et al, versus Joseph A Califano, Jr, et al. No. 76-1308, July 11, 1978.
451. United States Court of Appeals for the First Circuit: Robert F Bradley, et al, versus Caspar W Weinberger, Secretary of Health, Education, and Welfare et al. No. 73-1014, July 31, 1973.
452. United States District Court for the District of Columbia: Forsham et al, versus Mathews, et al. No. 75-1608, Sept 30, 1975.
453. United States District Court for the District of Columbia: Peter H Forsham et al, versus David Mathews, et al. No. 75-1608, Feb 5, 1976.
454. United States District Court for the District of Delaware: Pharmaceutical Manufacturers Association versus Robert H Finch, Secretary of Health, Education, and Welfare and Herbert L Ley, Jr, Commissioner of Food and Drugs. Affidavit of William Thomas Beaver, MD. Civil action no. 3797, 1969.
455. United States District Court for the District of Delaware: Pharmaceutical Manufacturers Association versus Elliot Richardson, Secretary of Health, Education, and Welfare and Charles C Edwards, Commissioner of Food and Drugs. Order denying preliminary injunction and granting summary judgment of dismissal. Civil action no. 3946, Oct 20, 1970.
456. United States District Court for the District of Maryland: Shirley Bailey et al. versus Robert J Lally, etc., et al. Civ nos. K-74-1102, K-75-1370, K-75-1371 and K-75-1372, July 21, 1979.
457. United States District Court for the Southern District of New York: Ciba-Geigy Corporation versus David Mathews, et al. No. 75 Civ 5049, Oct 14, 1975.
458. United States District Court for the Southern District of New York: Ciba-Geigy Corporation versus David Mathews, et al. No. 75 Civ 5049 (CHT), March 8, 1977.
459. United States Senate Select Committee on Small Business: Oral Hypoglycemic Drugs: Hearing before the Subcommittee on Monopoly, Sept 18, 19, and 20, 1974. Part 25, U.S. Government Printing Office, Washington, 1974.
460. United States Senate Select Committee on Small Business: Oral Hypoglycemic Drugs: Hearing before the Subcommittee on Monopoly, Jan 31, July 9-10, 1975. Part 28, U.S. Government Printing Office, Washington, 1975.
461. United States Supreme Court: Peter H Forsham, et al, versus Joseph A Califano, et al. Petition for a writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit, Oct term, 1978.
462. United States Supreme Court: Forsham, et al, versus Harris, Secretary of Health, Education and Welfare, et al. Certiorari to the United States Court of Appeals for the District of Columbia Circuit. No. 78-1118, argued Oct 31, 1979, decided March 3, 1980.
463. University of Chicago Press: The Chicago Manual of Style (13th ed). Chicago, 1982.
464. University Group Diabetes Program Research Group: The effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: 1. Design and methods (abstract). Diabetes 19 (suppl 1):387, 1970a.
465. University Group Diabetes Program Research Group: The effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: 2. Findings at baseline (abstract). Diabetes 19 (suppl 1):374, 1970b.
466. University Group Diabetes Program Research Group: The effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: 3. Course and mortality (abstract). Diabetes 19 (suppl 1):375, 1970c.
467. University Group Diabetes Program Research Group: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods, and baseline characteristics. Diabetes 19 (suppl 2):747-783, 1970d.
468. University Group Diabetes Program Research Group: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 19 (suppl 2):785-830, 1970e.
469. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: III. Clinical implications of UGDP results. JAMA 218:1400-1410, 1971a.
470. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: IV. A preliminary report on phenformin results. JAMA 217:777-784, 1971b.
471. University Group Diabetes Program Research Group: The UGDP controversy: Clinical trials versus clinical impressions. Diabetes 21:1035-1040, 1972.
472. University Group Diabetes Program Research Group: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: V. Evaluation of phenformin therapy. Diabetes 24(suppl 1): 65-184, 1975.
473. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 25:1129-1153, 1976.
474. University Group Diabetes Program Research Group: University Group Diabetes Program releases data on 1,027 patients. Diabetes 26:1195, 1977.
475. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA 240:37-42, 1978.
476. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: Final report. Diabetes 31(suppl 5): 1-81, 1982.
477. University Group Diabetes Program Research Group: Paper listing of baseline and follow-up data on UGDP patients (one volume per treatment group). No. PB 83-136-325. National Technical Information Service (NTIS), Springfield, VA, 1983a.
478. University Group Diabetes Program Research Group: Magnetic tape of baseline and follow-up data on UGDP patients. No. PB 83-129-122. National Technical Information Service (NTIS), Springfield, VA, 1983b.
479. V. Veterans Administration Cooperative Studies Program: Guidelines for VA Cooperative Studies (5th ed). Washington, April, 1982.
480. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 202:1028-1034, 1967.
481. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213:1143-1152, 1970.
482. Vonderlehr RA, Clark T, Wenger OC, Heller JR Jr: Untreated syphilis in the male Negro: A comparative study of treated and untreated cases. J Vener Dis Inform 17:260-265, 1936.
483. W. Wade N: Food Board's fat report hits fire: Academy discovers Cassandra's problem: What good is the truth if its not spreadable? Science 209:248-250, 1980.
484. Wald A: Sequential Analysis. John Wiley and Sons, New York, 1947.
485. Warner R, Wolfe SM, Rich R: Off Diabetes Pills: A Diabetic's Guide to Longer Life. Public Citizen's Health Research Group, Washington, 1978.
486. Waterhouse B: A Prospect of Exterminating the Small Pox. Cambridge Press, Cambridge, 1800.
487. Waterhouse B: A Prospect of Exterminating' the Small Pox. (part II). University Press, Cambridge, 1802.
488. Watson BL: Disclosure of computerized health care information. Am J Law Medicine 7:265-300, 1981.
489. Wei LJ, Durham S: The randomized play-the-winner rule in medical trials. JASA 73:840-843, 1978.
490. Weichert BG: Health care expenditures (in Health-United States 1981, pp 81-85). Publ no. (PHS) 82-1232, Department of Health and Human Services, Washington, 1981.
491. Weik MH: Standard Dictionary of Computers and Information Processing. Hayden Book Company, Inc, New York, 1970.
492. West KM: Recent trends in dietary management (pp 67-89 in Clinical Diabetes:Modern Management, edited by S Podolsky). Appleton-Century-Crofts, New York, 1980.
493. Williams ME, Lannon L, O'Donnell R, Barth SN (editors): Computer-Readable Data Bases: A Directory and Data Sourcebook. American Society for Information Science, Washington, 1979.
494. Woodward, WE: Informed consent of volunteers: A direct measurement of comprehension and retention of information. Clinical Research 27:248-252, 1979.
495. Woolf HB (editor in chief): Webster's New Collegiate Dictionary. G and C Merriam Co, Springfield, Mass, 1981.
496. Working Group on Arteriosclerosis: Decline in coronary heart disease mortality, 1968-78 (in Arteriosclerosis 1981, vol 2, pp 159-263). Publ no. 82-2035, National Heart, Lung, and Blood Institute, Bethesda, Md, Sept, 1981.
497. Wright IS, Marple CD, Beck DF: Myocardial Infarction: Its Clinical Manifestations and Treatment with Anticoagulants: A Study of 1,031 Cases (Report of the Committee on Anticoagulants). Grune and Stratton, New York, 1954.
498. Wright P, Haybittle J: Design of forms for clinical trials (1) Br Med J 2:529-530, 1979a.
499. Wright P, Haybittle J: Design of forms for clinical trials (2) Br Med J 2:590-592, 1979b.
500. Wright P, Haybittle J: Design of forms for clinical trials (3) Br Med J 2:650-651, 1979c.
501. Z. Zdep SM, Rhodes IN, Schwarz RM, Kilkenny MJ: The validity of the randomized response technique. Public Opinion Quart 43:544-549, 1979.
502. Zelen M: Play the winner rule and the controlled clinical trial. JASA 64:131-146, 1969.
503. Zelen M. A new design for randomized clinical trials. N Engl J Med 300:1242-1245, 1979.
504. Zelnio RN: Data collection techniques: Mail questionnaires. Am J Hosp Pharm 37:1113-1119, 1980.
505. Zukel WJ: Evolution and funding of the Coronary Drug Project. Controlled Clin Trials 4:281-312, 1983.